SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-028383
Filing Date
2023-04-10
Accepted
2023-04-10 06:16:21
Documents
13
Period of Report
2023-04-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea176728-8k_unicycive.htm   iXBRL 8-K 26136
2 FORM OF AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT ea176728ex10-1_unicycive.htm EX-10.1 10128
  Complete submission text file 0001213900-23-028383.txt   213931

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE uncy-20230406.xsd EX-101.SCH 3230
4 XBRL LABEL FILE uncy-20230406_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE uncy-20230406_pre.xml EX-101.PRE 22361
7 EXTRACTED XBRL INSTANCE DOCUMENT ea176728-8k_unicycive_htm.xml XML 3696
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

IRS No.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 23809631
SIC: 2834 Pharmaceutical Preparations